ДИССЕМИНИРОВАННЫЙ РАК ЯИЧНИКОВ: ВОЗМОЖНОСТИ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ (ОБЗОР ЛИТЕРАТУРЫ)
Аннотация
Обсуждаются современные данные литературы по вопросам хирургического лечения рака яичников, в том числе о необходимости выполнения оптимальных циторедуктивных операций (первичных или промежуточных), целесообразности выполнения лимфаденэктомии при диссеминированном раке яичников, возможности комбинированных операций, а также рассматриваются перспективы использования лапароскопии при данной патологии.
Ключевые слова
Об авторах
С. В. Молчанов
Томский НИИ онкологии
Россия
634050, г. Томск, пер. Кооперативный 5
Россия
634050, г. Томск, пер. Кооперативный 5
Л. А. Коломиец
Томский НИИ онкологии
Россия
634050, г. Томск, пер. Кооперативный 5
Россия
634050, г. Томск, пер. Кооперативный 5
Список литературы
1. Angioli R., Palaia I., Zullo M.A., Muzii L., Manci N., Calcagno M., Panici P.B. Diagnostic open laparoscopy in the management of advanced ovarian cancer // Gynecol. Oncol. 2006. Vol. 100. P. 455–461.
2. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a metaanalysis // Gynecol. Oncol. 2006. Vol. 103. P. 1070–1076.
3. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., Douglas J., Burger R.A., Armstrong D., Wenham R., McGuire W. Phase II study of bevacizumab in patients with platinumresistant ovarian cancer or peritoneal serous cancer // J. Clin. Oncol. 2007. Vol. 25. P. 5180–5186.
4. Chan J.K., Urban R., Hu J.M., Shin J.Y., Husain A., Teng N.N., Berek J.S., Osann K., Kapp D.S. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients // Br. J. Cancer. 2007. Vol. 96. P. 1817–1822.
5. Chi D.S., Abu-Rustum N.R., Sonoda Y., Awtrey C., Hummer A., Venkatraman E.S., Franklin C.C., Hamilton F., Gemignani M.L., Barakat R.R. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy // Am. J. Obstet. Gynecol. 2004. Vol. 191. P. 1138–1145.
6. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Hensley M., Barakat R.R. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? // Gynecol. Oncol. 2006. Vol. 103. P. 559–564.
7. Colombo N., Peiretti M., Parma G., Lapresa M., Mancari R., Carinelli S., Sessa C., Castiglione M. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2010. Vol. 21. Suppl. 5. P. 23–30. doi: 10.1093/annonc/mdq244.
8. Di Giorgio A., Cardi M., Biacchi D., Sibio S., Accarpio F., Ciardi A., Cornali T., Framarino M., Sammartino P. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases // World J. Surg. Oncol. 2013. Vol. 11. P. 64–72. doi: 10.1186/1477-7819-11-64.
9. du Bois A., Reuss A., Harter P., Pujade-Lauraine E., Ray-Coquard I., Pfisterer J. Potential Role of Lymphadenectomy in Advanced Ovarian Cancer: A Combined Exploratory Analysis of Three Prospectively Randomized Phase III Multicenter Trials // J. Clin. Oncol. 2010. Vol. 28. P. 1733–1739. doi: 10.1200/JCO.2009.25.3617.
10. du Bois A., Reuss A., Pujade-Lauraine E., Harter P., Ray-Coquard I., Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGOOVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) // Cancer. 2009. Vol. 115. P. 1234–1244. doi: 10.1002/cncr.24149.
11. Eisenkop S.M., Friedman R.L., Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study // Gynecol. Oncol. 1998. Vol. 69. P. 103–108.
12. Fagotti A., Fanfani F., Ludovisi M., Lo Voi R., Bifulco G., Testa A.C., Scambia G. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study // Gynecol. Oncol. 2005. Vol. 96. P. 729–735.
13. Gagliardi M.L., Polito S., Fagotti A., Fanfani F., Scambia G. Narrow-Band Imaging for Recurrent Ovarian Cancer // J. Minimally Invasive Gynecol. 2013. Vol. 20. Issue 1. P. 10–12. doi: 10.1016/j. jmig.2012.01.016.
14. Glehen O., Mohamed F., Gilly F.N. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia // Lancet Oncol. 2004. Vol. 5. P. 219–228.
15. Griffith C.T. Surgical resections of tumour bulk in the primary treatment of ovarian carcinoma // National Cancer Institute Monograph. 1975. Vol. 42. P. 101–104.
16. Harter P., Gnauert K., Hils R., Lehmann T.G., Fisseler-Eckhoff A., Traut A., du Bois A. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer // Int. J. Gynecol. Cancer. 2007. Vol. 17. P. 1238–1244.
17. Houvenaeghel G., Gutowski M., Buttarelli M., Cuisenier J., Narducci F., Dalle C., Ferron G., Morice P., Meeus P., Stockle E., Bannier M., Lambaudie E., Rouanet P., Fraisse J., Leblanc E., Dauplat J., Querleu D., Martel P., Castaigne D. Modified Posterior Pelvic Exenteration for Ovarian Cancer // Int. J. Gynecol. Cancer. 2009. Vol. 19. Issue 5. P. 968–973. doi: 10.1111/IGC.0b013e3181a7f38b.
18. Leblanc E., Querleu D., Narducci F., Occelli B., Papageorgiou T., Sonoda Y. Laparoscopic staging of early stage invasive adnexal tumors: a 10-year experience // Gynecol. Oncol. 2004. Vol. 94. P. 624–629.
19. Mandato V.D., Abrate M., De Iaco P., Pirillo D., Ciarlini G., Leoni M., Comerci G., Ventura A., Lenzi B., Amadori A., Rosati F., Martinello R., De Palma R., Ventura C., Belotti L.M., Formisano D., La Sala G.B. Clinical governance network for clinical audit to improve quality in epithelial ovarian cancer management // J. Ovarian Res. 2013. Vol. 6. P. 19–26. doi: 10.1186/1757-2215-6-19.
20. Marszalek A., Alran S., Scholl S., Fourchotte V., Plancher C., Rosty C., Meyniel J.P., De Margerie V., Dorval T., De La Rochefordière A., Cottu P., Petrow P., Sastre-Garrau X., Salmon R.J. Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute // Int. J. Surg. Oncol. 2010; 2010: 214919. doi: 10.1155/2010/214919.
21. Meigs J.V. Tumors of the Female Pelvic Organs. New York: MacMillan, 1934. P. 262–263.
22. Muñoz-Casares F.C., Rufián S., Arjona-Sánchez A., Rubio M.J., Díaz R., Casado Á., Naranjo Á., Díaz-Iglesias C.J., Ortega R., MuñozVillanueva M.C., Muntané J., Aranda E. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study // Cancer Chemother. Pharmacol. 2011. Vol. 68. P. 267–274. doi: 10.1007/s00280-011-1646-4.
23. Nezhat F.R., Pejovic T., Finger T.N., Khalil S.S. Role of Minimally Invasive Surgery in Ovarian Cancer // J. Minimally Invasive Gynecol. 2013. Vol. 20. P. 754–765. doi: 10.1016/j.jmig.2013.04.027.
24. Onda T., Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions // Expert Rev. Anticancer Ther. 2011. Vol. 11. P. 1053–1067. doi: 10.1586/era.11.24. Review.
25. Panici P.B., Maggioni A., Hacker N., Landoni F., Ackermann S., Campagnutta E., Tamussino K., Winter R., Pellegrino A., Greggi S., Angioli R., Manci N., Scambia G., Dell’Anna T., Fossati R., Floriani I., Rossi R.S., Grassi R., Favalli G., Raspagliesi F., Giannarelli D., Martella L., Mangioni C. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial // J. Natl. Cancer Inst. 2005. Vol. 97. P. 560–566.
26. Rauh-Hain J.A., Rodriguez N., Growdon W.B., Goodman A.K., Boruta D.M. 2nd, Horowitz N.S., del Carmen M.G., Schorge J.O. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer // Ann. Surg. Oncol. 2012. Vol. 19 (3). P. 959–965. doi: 10.1245/ s10434-011-2100-x.
27. Rutten M.J., Gaarenstroom K.N., Van Gorp T., van Meurs H.S., Arts H.J., Bossuyt P.M., Ter Brugge H.G., Hermans R.H., Opmeer B.C., Pijnenborg J.M., Schreuder H.W., Schutter E.M., Spijkerboer A.M., Wensveen C.W., Zusterzeel P., Mol B.W., Kenter G.G., Buist M.R. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study // BMC Cancer. 2012. Vol. 12. P. 31. doi: 10.1186/1471-2407-12-31.
28. Sugarbaker P.H., Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy // Ann. Surg. Oncol. 1999. Vol. 6. P. 727–731.
29. Valle M., Van Der Speeten K., Garofalo A. Laparoscopic Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) in the Management of Refractory Malignant Ascites: A Multi-Institutional Retrospective Analysis in 52 Patients // J. Surg. Oncol. 2009. Vol. 100. P. 331–334. doi: 10.1002/jso.21321.
30. Vergote I., Tropé C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., Kenter G.G., Casado A., Mendiola C., Coens C., Verleye L., Stuart G.C., Pecorelli S., Reed N.S. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer // N. Engl. J. Med. 2010. Vol. 363. P. 943–953. doi: 10.1056/NEJMoa0908806.
31. Whitney C.W., Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. 2010 January: [Электронный документ] (https:// gogmember.org/manuals/pdf/surgman.pdf).
32. Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) // Gynecol. Oncol. 2007. Vol. 106. P. 69–74.
33. Winter W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S., Rose P.G., Rubin S.C., Muggia F., McGuire W.P. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study // J. Clin. Oncol. 2007. Vol. 25. P. 3621–3627.
34. Winter W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S., Rose P.G., Rubin S.C., Muggia F., McGuire W.P. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study // J. Clin. Oncol. 2008. Vol. 26. P. 83–89.
Рецензия
Для цитирования:
Молчанов С.В., Коломиец Л.А. ДИССЕМИНИРОВАННЫЙ РАК ЯИЧНИКОВ: ВОЗМОЖНОСТИ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ (ОБЗОР ЛИТЕРАТУРЫ). Сибирский онкологический журнал. 2014;(5):54-59.
For citation:
Molchanov S.V., Kolomiets L.A. DISSEMINATED OVARIAN CANCER: SURGICAL TREATMENT (LITERATURE REVIEW). Siberian journal of oncology. 2014;(5):54-59. (In Russ.)
Просмотров: 652
.png)
Послать статью по эл. почте 
